Vertex is extremely disappointed that Pharmac has decided
not to prioritise funding of Trikafta®
(elexacaftor/tezacaftor/ivacaftor and ivacaftor) for New
Zealand’s cystic fibrosis (CF) patients.
We
understand that Pharmac must make choices within a fixed
budget, about which patient groups will have access to new,
innovative medicines. However, we are surprised by this
decision, particularly given their recent public
acknowledgment of the clinical impact that Trikafta would
have on CF patients in New Zealand.
Vertex remains
committed to New Zealand’s CF community and will continue
to work collaboratively with Pharmac to find a path forward
so that those Kiwis who can benefit from Trikafta have the
same access as patients in more than 30 other countries
around the
world.
© Scoop Media
Discussion about this post